Zettl, Uwe Klaus; Rommer, Paulus Stefan; Aktas, Orhan; Wagner, Torsten; Richter, Joachim; Oschmann, Patrick; Cepek, Lukas; Elias-Hamp, Birte; Gehring, Klaus; Chan, Andrew; Hecker, Michael (2023). Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. Expert review of clinical immunology, 19(11), pp. 1343-1359. Taylor & Francis 10.1080/1744666X.2023.2248391
|
Text
Interferon_beta_1a_sc_at_25_years_a_mainstay_in_the_treatment_of_multiple_sclerosis_over_the_period_of_one_generation.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (4MB) | Preview |
INTRODUCTION
Interferon beta (IFN beta) preparations are an established group of drugs used for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in continuous clinical use for 25 years as a disease-modifying treatment.
AREAS COVERED
Based on data published since 2018, we discuss recent insights from analyses of the pivotal trial PRISMS and its long-term extension as well as from newer randomized studies with IFN beta-1a sc as the reference treatment, the use of IFN beta-1a sc across the patient life span and as a bridging therapy, recent data regarding the mechanisms of action, and potential benefits of IFN beta-1a sc regarding vaccine responses.
EXPERT OPINION
IFN beta-1a sc paved the way to effective immunomodulatory treatment of MS, enabled meaningful insights into the disease process, and remains a valid therapeutic option in selected vulnerable MS patient groups.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Chan, Andrew Hao-Kuang |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1744-8409 |
Publisher: |
Taylor & Francis |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
12 Sep 2023 09:48 |
Last Modified: |
25 Oct 2023 00:15 |
Publisher DOI: |
10.1080/1744666X.2023.2248391 |
PubMed ID: |
37694381 |
Uncontrolled Keywords: |
25 years Interferon beta-1a disease-modifying therapy generation long-term efficacy long-term safety mechanisms of action multiple sclerosis |
BORIS DOI: |
10.48350/186225 |
URI: |
https://boris.unibe.ch/id/eprint/186225 |
Actions (login required)
 |
Edit item |